Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366312 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
A Phase 2 study of Keratocystic Odontogenic Tumor, sponsored by NYU College of Dentistry.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT02366312 is a Phase 2 study of Keratocystic Odontogenic Tumor that has completed, run by NYU College of Dentistry. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02366312, a Phase 2 study of Keratocystic Odontogenic Tumor, has completed, sponsored by NYU College of Dentistry.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine how well a daily dose of 150 mg of Erivedge (vismodegib) reduces Keratocystic odontogenic tumor (KCOT) size, and to evaluate the safety of this dose. Erivedge is FDA-approved for use in adults with a specific type of skin cancer. However, the drug is experimental for patients with KCOT.
Conditions Studied
Interventions
- DRUG vismodegib
Study Locations (1)
New York
- NYU Bluestone Center For Cllinical Research - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-10-27 |
| Est. Completion | 2019-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366312
The ClinicalTrials.gov registry entry for NCT02366312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU College of Dentistry, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratocystic Odontogenic Tumor appearing as the primary indexed condition, and to 1 intervention - of which vismodegib is the first listed.
NCT02366312 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02366312 about?
NCT02366312 is a clinical study titled "A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors". The purpose of this study is to determine how well a daily dose of 150 mg of Erivedge (vismodegib) reduces Keratocystic odontogenic tumor (KCOT) size, and to evaluate the safety of this dose. Erivedge is FDA-approved for use in adults with a specific type of skin cancer. However, the drug is experim...
What is the current status of trial NCT02366312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-10-27. Estimated completion is 2019-08.
What conditions does trial NCT02366312 study?
This clinical trial studies the following conditions: Keratocystic Odontogenic Tumor.
What interventions are being tested in trial NCT02366312?
The interventions under investigation include: vismodegib (DRUG).
Who is sponsoring clinical trial NCT02366312?
This trial is sponsored by NYU College of Dentistry, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02366312 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.